CWCunChuan Wang

CunChuan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


CunChuan Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Huang

    Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China

    1 shared publication
  • Jinyu Qi

    Department of Gastrointestinal Surgery, The First Hospital of Quanzhou Affiliated of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China

    1 shared publication
  • Liangpan Shi

    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China

    1 shared publication
  • Peng Sun

    Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China

    1 shared publication
  • Weidong Wang

    Laboratory of Genetics and Genomics, National Institute on Aging, Baltimore, Maryland, USA

    1 shared publication
  • YiChao Zhang

    Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China

    1 shared publication

Latest Publications

  • MiR-138-5p Inhibits Thyroid Cancer Cell Growth and Stemness by Targeting TRPC5/Wnt/β-Catenin Pathway

    by Bo Huang, YiChao Zhang, Peng Sun, YuanYuan Yuan, CunChuan Wang

    MicroRNAs play a key role in the pathogenesis of many types of cancer, including thyroid cancer (TC). MiR-138-5p has been confirmed to be abnormally expressed in TC tissues. However, the role of miR-138-5p in TC progression and its potential molecular mechanism need to be further explored. In this study, quantitative real-time PCR was used to examine miR-138-5p and TRPC5 expression, and western blot analysis was performed to examine the protein levels of TRPC5, stemness-related markers, and Wnt pathway-related markers. Dual-luciferase reporter assay was used to assess the interaction between miR-138-5p and TRPC5. Cell proliferation, stemness, and apoptosis were examined using colony formation assay, sphere formation assay, and flow cytometry. Our data showed that miR-138-5p could target TRPC5 and its expression was negatively correlated with TRPC5 expression in TC tumor tissues. MiR-138-5p decreased proliferation, stemness, and promoted gemcitabine-induced apoptosis in TC cells, and this effect could be reversed by TRPC5 overexpression. Moreover, TRPC5 overexpression abolished the inhibitory effect of miR-138-5p on the activity of Wnt/β-catenin pathway. In conclusion, our data showed that miR-138-5p suppressed TC cell growth and stemness via the regulation of TRPC5/Wnt/β-catenin pathway, which provided some guidance for studying the potential function of miR-138-5p in TC progression.


  • Open Access

    miR‑146b‑5p promotes colorectal cancer progression by targeting TRAF6

    by Liangpan Shi, Yibin Su, Zhihua Zheng, Jinyu Qi, Weidong Wang, Cunchuan Wang

    Increasing evidence highlights the multiple roles of microRNAs (miRs) in the tumorigenesis of colorectal cancer (CRC); however, the molecular mechanism, particularly the target of miR‑146b‑5p in CRC has not been fully elucidated. The present study aimed to elucidate the influence of miR‑146b‑5p via regulating tumor necrosis factor receptor‑associated factor 6 (TRAF6) in CRC. The expression levels of miR‑146b‑5p and TRAF6 in CRC tissue and cells were determined by reverse transcription quantitative PCR and western blotting. Binding between miR‑146b‑5p and TRAF6 was examined using a dual luciferase reporter gene assay. The impact of miR‑146b‑5p and TRAF6 on proliferation and migration of CRC cells was determined using Cell Counting Kit‑8 and Transwell assays, respectively. An animal model of CRC was established to determine the carcinogenic effect of the miR‑146b‑5p‑TRAF6 axis. The results demonstrated that miR‑146b‑5p was highly expressed in CRC tissue samples compared with in normal adjacent tissue samples and in CRC cells compared with in the normal NCM460 cell line, whereas TRAF6 was expressed at low levels. Overexpression of miR‑146b‑5p decreased TRAF6 expression in CRC HT29 and SW620 cells. miR‑146b‑5p targeted and inhibited TRAF6 expression in CRC cells. Furthermore, transfection with a miR‑146b‑5p mimic promoted the proliferation, migration and invasion of CRC cells and tumor growth; however, these effects were abolished by TRAF6 overexpression. Transfection with a miR‑146b‑5p inhibitor suppressed the proliferation of CRC cells. Taken together, the results from the present study demonstrated that miR‑146b‑5p could enhance the initiation and tumorigenesis of CRC by targeting TRAF6. These results will help elucidate the mechanisms underlying CRC development and will facilitate the development of targeted therapy for CRC.